Lin Jui-Chu, Hsiao Wesley Wei-Wen, Fan Chien-Te
College of Liberal Arts and Social Sciences, National Taiwan University of Science and Technology, Taipei, Taiwan, ROC.
Law & Technology Innovation Center, National Taiwan University of Science and Technology, Taipei, Taiwan, ROC.
Comput Struct Biotechnol J. 2019 Aug 2;17:1135-1142. doi: 10.1016/j.csbj.2019.07.006. eCollection 2019.
In this article, incidental findings (IF) refer to unforeseen findings made possible through biobanking research and advances in medical diagnostic technologies that raise issues regarding the obligation and/or responsibility of biobank-users and biobanks to return clinically significant information to participants. The World Medical Association (WMA) Declaration of Taipei (2016) highlights the possibility of encountering IF and requires that research on biospecimens address biobank feedback policies in their informed consent process, leaving open the possibility that the policy may be "no return". As clinicians and researchers begin to use these "resources", the possibility of finding clinically significant IF is becoming a reality.
In line with the WMA's Declaration of Taipei, a pragmatic approach is needed to deal with the issue of returning IF in biobank governance. Indeed, the impacts and concerns associated with the return of IF differ across different stakeholder groups and jurisdictions. Therefore, the framework governing IF return needs to be custom-built, taking into account the nature of each research project and the unique features of biobanks. To this end, in addition to facilitating biobank transparency, establishing an endurable and horizontal connection among biobanks and clinical institutions under a public health system will improve efficiency and effectiveness. Hence, subject to contemporary Taiwanese ethical and/or legal regulations, this article argues for the establishment of an updated framework for imaging-related and genetic-related IF return within the Taiwan Biobank (TWB), mainly based on a limited obligation to disclose life-threatening information revealed by imaging, but not genetic, information.
After discussing some of the ethical, legal and social issues encountered by the TWB and accounting for the experiences of other international biobanks, we propose a systematic framework for returning IF, mainly on a "limited obligation" basis, which offers better and more comprehensive protection for biobank-participants' rights and health.
在本文中,偶然发现(IF)是指通过生物样本库研究和医学诊断技术进步而得以发现的意外发现,这些发现引发了关于生物样本库使用者和生物样本库向参与者反馈临床重要信息的义务和/或责任的问题。世界医学协会(WMA)《台北宣言》(2016年)强调了遇到偶然发现的可能性,并要求生物样本研究在知情同意过程中阐述生物样本库反馈政策,同时也留出了政策可能是“不反馈”的可能性。随着临床医生和研究人员开始使用这些“资源”,发现具有临床意义的偶然发现的可能性正成为现实。
根据WMA的《台北宣言》,在生物样本库管理中需要一种务实的方法来处理反馈偶然发现的问题。事实上,与反馈偶然发现相关的影响和担忧在不同利益相关者群体和司法管辖区之间存在差异。因此,管理偶然发现反馈的框架需要量身定制,要考虑到每个研究项目的性质和生物样本库的独特特征。为此,除了提高生物样本库的透明度外,在公共卫生系统下建立生物样本库与临床机构之间持久且横向的联系将提高效率和成效。因此,根据当代台湾的伦理和/或法律法规,本文主张在台湾生物样本库(TWB)内建立一个更新的与影像相关和基因相关的偶然发现反馈框架,主要基于有限义务披露由影像而非基因信息揭示的危及生命的信息。
在讨论了TWB遇到的一些伦理、法律和社会问题并考量了其他国际生物样本库的经验后,我们提出了一个主要基于“有限义务”的偶然发现反馈系统框架,该框架为生物样本库参与者的权利和健康提供了更好、更全面的保护。